Bayer wins China approval for stroke prevention drug asundexian
China's drug regulator approved Bayer's blood thinner asundexian for stroke prevention, marking the first approval globally for this new class of anticoagulant. The approval followed a priority review and represents a significant boost for Bayer's pharmaceutical pipeline.
